Mirum Pharmaceuticals (MIRM) Revenue & Revenue Breakdown
Mirum Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$336.89M
Latest Revenue (Q)
$111.58M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Mirum Pharmaceuticals Revenue by Period
Mirum Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2024-12-31 | $336.89M | 80.76% |
2023-12-31 | $186.37M | 141.85% |
2022-12-31 | $77.06M | 302.66% |
2021-12-31 | $19.14M | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | - |
Mirum Pharmaceuticals generated $336.89M in revenue during NA 2024, up 80.76% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Mirum Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2025-03-31 | $111.58M | 12.24% |
2024-12-31 | $99.41M | 10.00% |
2024-09-30 | $90.38M | 16.05% |
2024-06-30 | $77.88M | 12.50% |
2024-03-31 | $69.22M | -0.48% |
2023-12-31 | $69.55M | 45.74% |
2023-09-30 | $47.73M | 27.28% |
2023-06-30 | $37.50M | 18.67% |
2023-03-31 | $31.60M | 13.23% |
2022-12-31 | $27.91M | 48.59% |
2022-09-30 | $18.78M | 7.41% |
2022-06-30 | $17.48M | 35.62% |
2022-03-31 | $12.89M | 310.83% |
2021-12-31 | $3.14M | -37.24% |
2021-09-30 | $5.00M | -54.55% |
2021-06-30 | $11.00M | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | 100.00% |
2020-03-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | - |
Mirum Pharmaceuticals generated $111.58M in revenue during Q1 2025, up 12.24% compared to the previous quarter, and up 160.43% compared to the same period a year ago.
Mirum Pharmaceuticals Revenue Breakdown
Mirum Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|---|
License and Other Revenue | $479.00K | - | - | - |
Product | $336.41M | $178.87M | $75.06M | $3.14M |
License Revenue | - | $7.50M | - | - |
License | - | - | $2.00M | $16.00M |
Mirum Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (99.86%), and License and Other Revenue (0.14%).
Quarterly Revenue by Product
Product/Service | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Product | $127.78M | $111.58M | $177.19M | $90.30M | $68.92M | $69.55M | $47.73M | $32.50M | $29.10M | $27.91M | $18.78M | $17.48M | $10.89M |
License and Other Revenue | - | - | $99.00K | $75.00K | $305.00K | - | - | - | - | - | - | - | - |
License Revenue | - | - | - | - | - | - | $7.50M | - | - | - | - | - | - |
License | - | - | - | - | - | - | - | $5.00M | $2.50M | - | - | - | $2.00M |
Mirum Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product (100.00%).
Mirum Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
Country | Dec 24 | Dec 23 |
---|---|---|
Rest of the World | $62.24M | - |
UNITED STATES | $274.17M | $146.70M |
Rest of World | - | $32.17M |
Mirum Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (81.50%), and Rest of the World (18.50%).
Quarterly Revenue by Country
Country | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Mar 24 |
---|---|---|---|---|---|
UNITED STATES | $95.53M | $86.92M | $144.16M | $73.91M | $56.11M |
Rest Of World | $32.25M | $24.66M | $16.40M | $12.81M | - |
Mirum Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Jun 25: UNITED STATES (74.76%), and Rest Of World (25.24%).
Mirum Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
KNSA | Kiniksa Pharmaceuticals | $423.24M | $156.80M |
MIRM | Mirum Pharmaceuticals | $336.89M | $111.58M |
DAWN | Day One Biopharmaceuticals | $131.16M | $33.91M |
PHAT | Phathom Pharmaceuticals | $55.25M | $39.50M |
FULC | Fulcrum Therapeutics | $2.81M | - |
CRNX | Crinetics Pharmaceuticals | $1.04M | $361.00K |
GPCR | Structure Therapeutics | - | - |
REPL | Replimune Group | - | - |